Diagnosing Alzheimer’s Disease: MCI to Dimentia– Imaging Biomarkers in Clinical Practice- Alzheimer’s disease (AD) is a progressive neurodegenerative disease whose prevalence increases with advancing age. The underlying pathologic processes are being extensively investigated, and cranial imaging and cerebral spinal fluid markers support the current amyloid beta cascade model. Clinically, the later stages of AD present as dementia and selective memory impairment. Symptomatic treatments are available but there is no cure and the cognitive impairment characteristic of AD inevitably progresses in all patients. The discovery that AD has a gradual onset over many years has led to new diagnostic guidelines and an understanding that the neurodegeneration of AD may be caused by the deposition of amyloid beta-peptide in plaques in brain tissue.
This activity will examine the amyloid plaque model, discuss and apply the new National Institute of Aging/Alzheimer’s Association (NIA/AA) diagnostic guidelines to all stages of AD, and review the use of amyloid cerebral PET imaging in AD.
Review the amyloid hypothesis and the pathophysiology associated with AD.
Apply the NIA/AA diagnostic guidelines to the evaluation of patients at all stages of AD.
Discuss the use of cerebral amyloid imaging for AD in the clinical setting.
1.0 Free ASRT CEUs for Radiology Technologists
This course also offers Free CEUs for Physicians and Nurses